Drug delivery to the eye for the treatment of cataracts
What is it about?
Oxidative damage due to low levels of glutathione (GSH) is one of the main causes of cataract formation. A cysteine prodrug, 2-oxothiazolidine-4-carboxylic acid (OTZ), can increase the cellular level of GSH. We have developed a method for determining OTZ content and have used this to determine the loading of nanoparticles containing this drug.
Why is it important?
The paper is a stepping stone to developing therapeutic strategies for treating or preventing cataracts.
The following have contributed to this page: Dr James R Smith
In partnership with: